Viridian Therapeutics (VRDN) Stock Overview
Engages in discovering, developing, and commercializing treatments for serious and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VRDN Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.02 |
| 52 Week High | US$33.34 |
| 52 Week Low | US$9.90 |
| Beta | 0.91 |
| 1 Month Change | 16.69% |
| 3 Month Change | 61.64% |
| 1 Year Change | 62.37% |
| 3 Year Change | 18.37% |
| 5 Year Change | 74.88% |
| Change since IPO | -82.36% |
Recent News & Updates
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues
Nov 22
Analysts' Revenue Estimates For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Are Surging Higher
Nov 10Viridian Therapeutics Is Ready For An Eventful 2026
Nov 06Recent updates
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues
Nov 22Analysts' Revenue Estimates For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Are Surging Higher
Nov 10Viridian Therapeutics Is Ready For An Eventful 2026
Nov 06Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?
Jul 01Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
Mar 02Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?
Feb 11Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value?
Dec 20We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate
Nov 14Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Sep 11Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Sep 10Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Jun 12Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?
May 28Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt
Sep 12Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?
May 15Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Apr 18Shareholder Returns
| VRDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -1.3% | 0.5% |
| 1Y | 62.4% | 16.9% | 12.1% |
Return vs Industry: VRDN exceeded the US Biotechs industry which returned 16.9% over the past year.
Return vs Market: VRDN exceeded the US Market which returned 12.1% over the past year.
Price Volatility
| VRDN volatility | |
|---|---|
| VRDN Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VRDN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VRDN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 143 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| VRDN fundamental statistics | |
|---|---|
| Market cap | US$3.06b |
| Earnings (TTM) | -US$245.32m |
| Revenue (TTM) | US$70.79m |
Is VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRDN income statement (TTM) | |
|---|---|
| Revenue | US$70.79m |
| Cost of Revenue | US$318.18m |
| Gross Profit | -US$247.39m |
| Other Expenses | -US$2.07m |
| Earnings | -US$245.32m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.57 |
| Gross Margin | -349.48% |
| Net Profit Margin | -346.55% |
| Debt/Equity Ratio | 4.2% |
How did VRDN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 12:23 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viridian Therapeutics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Leah Rush Cann | Brookline Capital Markets |
| Julian Harrison | BTIG |